Laboratory Net Worth
Laboratory Net Worth Breakdown | LH |
Laboratory Net Worth Analysis
Laboratory's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Laboratory's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Laboratory's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Laboratory's net worth analysis. One common approach is to calculate Laboratory's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Laboratory's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Laboratory's net worth. This approach calculates the present value of Laboratory's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Laboratory's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Laboratory's net worth. This involves comparing Laboratory's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Laboratory's net worth relative to its peers.
Enterprise Value |
|
To determine if Laboratory is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Laboratory's net worth research are outlined below:
| Laboratory has a strong financial position based on the latest SEC filings | |
| Over 100.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Caitong International Asset Management Co. Ltd Invests 118,000 in Labcorp Holdings Inc. |
Laboratory Quarterly Good Will |
|
Laboratory uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Laboratory of. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Laboratory's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 15th of February 2024 Upcoming Quarterly Report | View | |
| 23rd of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 15th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Laboratory's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Laboratory is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Laboratory of backward and forwards among themselves. Laboratory's institutional investor refers to the entity that pools money to purchase Laboratory's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 1.6 M | Amvescap Plc. | 2025-03-31 | 1.4 M | Dimensional Fund Advisors, Inc. | 2025-06-30 | 1.3 M | Alliancebernstein L.p. | 2025-03-31 | 1.3 M | Jpmorgan Chase & Co | 2025-03-31 | 1.3 M | Amundi | 2025-03-31 | 1.1 M | Veritas Investment Partners (uk) Ltd. | 2025-06-30 | 1.1 M | Ubs Asset Mgmt Americas Inc | 2025-06-30 | 1 M | Northern Trust Corp | 2025-03-31 | 1 M | Vanguard Group Inc | 2025-06-30 | 9.9 M | Blackrock Inc | 2025-03-31 | 9.3 M |
Follow Laboratory's market capitalization trends
The company currently falls under 'Large-Cap' category with a market capitalization of 22.47 B.Market Cap |
|
Project Laboratory's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.09 | 0.14 | |
| Return On Capital Employed | 0.07 | 0.07 | |
| Return On Assets | 0.04 | 0.04 | |
| Return On Equity | 0.09 | 0.18 |
When accessing Laboratory's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Laboratory's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Laboratory's profitability and make more informed investment decisions.
Evaluate Laboratory's management efficiency
Laboratory has Return on Asset (ROA) of 0.0444 % which means that for every $100 of assets, it generated a profit of $0.0444. This is way below average. Likewise, it shows a return on total equity (ROE) of 0.0926 %, which means that it produced $0.0926 on every 100 dollars invested by current stockholders. Laboratory's management efficiency ratios could be used to measure how well Laboratory manages its routine affairs as well as how well it operates its assets and liabilities. As of now, Laboratory's Return On Tangible Assets are decreasing as compared to previous years. The Laboratory's current Return On Equity is estimated to increase to 0.18, while Return On Capital Employed is projected to decrease to 0.07. As of now, Laboratory's Total Current Assets are increasing as compared to previous years. The Laboratory's current Other Assets is estimated to increase to about 684.8 M, while Non Currrent Assets Other are projected to decrease to under 399 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 96.14 | 100.95 | |
| Tangible Book Value Per Share | (21.36) | (22.43) | |
| Enterprise Value Over EBITDA | 13.80 | 10.98 | |
| Price Book Value Ratio | 2.39 | 3.26 | |
| Enterprise Value Multiple | 13.80 | 10.98 | |
| Price Fair Value | 2.39 | 3.26 | |
| Enterprise Value | 7.4 B | 7.8 B |
Examining the leadership quality of Laboratory of offers valuable insights into its operational efficiency and financial health. This analysis assists investors in making informed decisions regarding the stock.
Enterprise Value Revenue 2.1038 | Revenue | Quarterly Revenue Growth 0.095 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Laboratory insiders, such as employees or executives, is commonly permitted as long as it does not rely on Laboratory's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Laboratory insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Laboratory Corporate Filings
F4 | 15th of August 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 24th of July 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 30th of May 2025 Other Reports | ViewVerify | |
| 29th of May 2025 Other Reports | ViewVerify |
Laboratory Earnings per Share Projection vs Actual
Laboratory Corporate Directors
| Kerrii Anderson | Independent Director | Profile | |
| JeanLuc Belingard | Independent Director | Profile | |
| Peter Neupert | Lead Independent Director | Profile | |
| Richelle Parham | Independent Director | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Laboratory of. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Laboratory. If investors know Laboratory will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Laboratory listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.169 | Dividend Share 2.88 | Earnings Share 9.06 | Revenue Per Share | Quarterly Revenue Growth 0.095 |
The market value of Laboratory is measured differently than its book value, which is the value of Laboratory that is recorded on the company's balance sheet. Investors also form their own opinion of Laboratory's value that differs from its market value or its book value, called intrinsic value, which is Laboratory's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Laboratory's market value can be influenced by many factors that don't directly affect Laboratory's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Laboratory's value and its price as these two are different measures arrived at by different means. Investors typically determine if Laboratory is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Laboratory's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.